Skip to Main Content

Microbial Fermentation

Animal-origin-free proteins for microbial recombinant-protein production.

Recombinant human lysozyme releases protein from the bacterial host, and recombinant human albumin stabilizes the drug product through formulation, replacing egg-derived enzyme and plasma-derived albumin.

Where our products fit

The Fermentation workflow, step by step.

The microbial antibody workflow, step by step, and where InVitria recombinant proteins fit.

Seed Train & Inoculum Expansion

Expand the banked strain through shake-flask and seed-fermenter stages into inoculum for the production fermenter.

Overview

Seed train expansion grows the banked strain through progressively larger vessels, typically shake flasks followed by one or more seed fermenters, to build enough viable biomass to inoculate the production fermenter at the target starting density.

Each stage is monitored for optical density, growth rate, and, for plasmid-based strains, selection-marker retention, since a seed culture that has lost plasmid copy number or drifted genetically will underperform or fail to express the target protein at production scale.

Microbial seed media are built around defined or complex carbon and nitrogen sources (glucose or glycerol, yeast extract or defined amino acid mixes) and selective antibiotics, formulated for prokaryotic or fungal growth kinetics rather than the growth-factor and carrier-protein requirements of mammalian cell culture.

Fermentation (Batch/Fed-Batch)

Grow the strain to high density and induce target protein expression in batch or fed-batch fermentation.

Overview

Fermentation is the production phase: the strain is grown in a stirred-tank fermenter, in batch or fed-batch mode, to high cell density, then induced (chemically, by temperature shift, or by nutrient depletion, depending on the expression system) to produce the target recombinant protein.

Fed-batch operation, feeding a concentrated carbon source to control growth rate and avoid overflow metabolism (such as acetate accumulation in E. coli), is the standard approach for reaching the high cell densities that maximize volumetric protein titer.

Fermentation medium and feed design center on carbon-source feed strategy, dissolved-oxygen and pH control, and induction chemistry, engineering disciplines specific to microbial physiology and distinct from the animal-origin-free protein supplementation used in mammalian cell culture media.

Cell Harvest & Lysis

Lyse the harvested biomass with recombinant lysozyme delivering over 4x the specific activity of egg-derived lysozyme, releasing intracellular target protein without an allergen-bearing input.

Overview

Cell harvest separates the fermentation biomass from spent broth, typically by centrifugation, and lysis then breaks the cell wall and membrane to release the target protein, required whenever the product accumulates intracellularly rather than being secreted, which is the common case for E. coli expression.

Lysis is achieved mechanically (high-pressure homogenization, bead milling) or enzymatically, using lysozyme to hydrolyze the peptidoglycan cell wall, often combined with a mild mechanical or freeze-thaw step to complete membrane disruption. Enzymatic lysis is gentler on the released protein than high-shear mechanical methods and scales more predictably.

Lysozyme source and specific activity determine dose and process efficiency: a recombinant, non-egg-derived lysozyme with substantially higher specific activity than the traditional chicken-egg source lyses biomass at lower dose, without introducing an egg-allergen protein into a process stream headed for a biologic drug substance.

Functions

Bacterial Lysis

Bacterial cell walls are cross-linked peptidoglycan, alternating N-acetylglucosamine and N-acetylmuramic acid residues joined by beta(1,4) glycosidic bonds and peptide cross-links, that give the wall its mechanical strength and osmotic resistance. Hydrolyzing these beta(1,4) bonds compromises the wall’s structural integrity, and in a hypotonic lysis buffer the cell then ruptures under its own internal osmotic pressure, releasing cytoplasmic content including the intracellular target protein.

Recommendation
Lysobac®

Recombinant human lysozyme powder for bacterial cell lysis, protein recovery, diagnostic assays, and life science research.

Commonly replaces
Egg-derived lysozyme and, in some processes, high-shear mechanical disruption used alone for cell lysis.

Inclusion-Body Solubilization & Refolding

For E. coli products expressed as inclusion bodies, solubilize with chaotrope and refold to the native, active conformation before purification. Soluble/secreted products skip this step.

Overview

Many E. coli-expressed proteins accumulate as insoluble inclusion bodies. After lysis, inclusion bodies are recovered and solubilized (urea or guanidine with a reducing agent), then refolded by controlled dilution or dialysis with a redox couple to restore native disulfide bonding and activity. Refolding yield governs overall process economics.

Clarification

Clarify the lysate with recombinant albumin blocking nonspecific surface adsorption, protecting low-concentration target protein through filtration and centrifugation.

Overview

Clarification removes cell debris, insoluble aggregates, and colloidal material from the lysate, typically by centrifugation followed by depth or membrane filtration, to produce a particulate-free feed for chromatographic purification.

At this stage the target protein is often at low concentration relative to total lysate protein and is exposed to a large surface area across filters, centrifuge internals, and holding vessels. Nonspecific adsorption of protein to these surfaces is a well-documented mechanism of yield loss, disproportionately affecting low-concentration process streams.

A carrier protein added to the clarification stream competitively occupies available binding surface, reducing target-protein loss to adsorption without requiring changes to filter or centrifuge equipment already qualified for the process.

Functions

Anti-Adsorption

Protein loss to surface adsorption during clarification follows a saturable binding process: process-contact surfaces (filters, tubing, vessel walls) present finite nonspecific binding sites that any protein in the stream competes for. At low target-protein concentration relative to surface area, a disproportionate fraction can be lost to adsorption. A carrier protein at higher concentration saturates this capacity, sparing the target from surface loss.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived albumin or other blocking proteins used to reduce nonspecific adsorption during clarification.

Purification

Protect the target protein through chromatographic purification with recombinant albumin blocking nonspecific adsorption to resin and hardware surfaces.

Overview

Purification isolates the target protein from the clarified lysate through one or more chromatography steps, commonly affinity capture followed by ion-exchange and/or size-exclusion polishing, each selected to remove a distinct class of process- and product-related impurities.

Every chromatography step and every length of tubing, valve, and holding vessel between them presents surface area to which protein can nonspecifically adsorb, a loss mechanism that is most consequential during intermediate purification steps, where the target is often at its most dilute relative to total surface exposure across a multi-column train.

A carrier protein included in intermediate holding buffers or low-concentration column fractions competes for the same nonspecific binding sites, reducing target-protein loss between purification steps without altering resin chemistry or chromatography method.

Endotoxin (lipopolysaccharide) clearance is a defining requirement for E. coli products and is achieved here (e.g., anion-exchange, Triton X-114 phase separation, or dedicated endotoxin-removal media) to meet injectable limits.

Functions

Anti-Adsorption

Chromatography resins, membranes, and hardware present nonspecific protein-binding surface independent of the chromatographic mechanism (affinity, ion-exchange, size-exclusion). Target protein at low concentration, particularly in dilute intermediate fractions or extended hold steps between columns, is vulnerable to adsorptive loss. A carrier protein at higher concentration occupies this capacity preferentially, protecting recovery through the purification train.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived albumin or detergent-based blocking agents used to limit nonspecific adsorption during purification.

Concentration & Buffer Exchange

Stabilize the purified protein through concentration and buffer exchange with recombinant albumin, limiting aggregation and interfacial loss during ultrafiltration.

Overview

Concentration and buffer exchange, typically performed by tangential flow filtration (ultrafiltration/diafiltration), raise the purified protein to its target concentration and transfer it into the buffer used for formulation or the next process step.

This step concentrates the protein at the same time it exposes it to shear at the membrane surface and to new air-liquid and solid-liquid interfaces, conditions known to promote aggregation and interfacial denaturation, and the risk rises as protein concentration and processing time increase.

A stabilizing carrier protein included through this step limits interfacial and shear-driven aggregation, helping the target protein reach its final concentration and buffer with recovery and quality intact.

Functions

Protein Stabilization

Ultrafiltration/diafiltration exposes protein to recirculation shear at the membrane surface and repeated air-liquid interface formation as retentate concentrates, both known drivers of unfolding and aggregation. Aggregation risk rises with protein concentration and processing time, both of which increase during this step. A stabilizing protein in the stream can reduce interfacial and shear-driven unfolding, supporting structural integrity through concentration.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived albumin used as a stabilizing excipient during ultrafiltration/diafiltration.

Formulation & Fill

Formulate the recombinant protein into its final matrix with a defined, animal-origin-free recombinant albumin excipient, then fill it into its final container.

Overview

Formulation and fill bring the purified recombinant protein to its finished form, a liquid or lyophilized product in the buffer, stabilizers, and excipients selected to maintain potency over its intended shelf life, then filled into its final container (vial, syringe, or bulk container depending on end use).

Albumin is a standard excipient in protein-product formulations, acting as a stabilizer and, at low target-protein concentration, as a carrier that limits adsorptive and interfacial loss during fill. Because this is the finished product, excipient sourcing and quality carry directly into the product’s regulatory and safety profile.

A defined, animal-origin-free recombinant albumin fills this excipient role while keeping the final formulation free of plasma-derived material, and is available in liquid or lyophilized format depending on the target product’s storage and reconstitution requirements.

Functions

Formulation Excipient

In final formulation, protein products, particularly at low or moderate concentration, are vulnerable to aggregation, adsorptive loss to container and fill-line surfaces, and interfacial stress during filling. Albumin included as a formulation excipient buffers against these stresses, stabilizing the product through fill and into storage. As a drug-substance or drug-product-adjacent excipient, its purity and sourcing carry into the finished product’s quality and regulatory profile.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a formulation excipient.

One animal-origin-free toolkit across every microbial fermentation workflow.

Microbial protein workflows share the same raw-material risks: egg proteins and allergens in the enzyme that releases protein from the bacterial host, lot-to-lot variability tied to extraction yields, and plasma-derived albumin at the stabilization stage, with its adventitious agent risk and rising regulatory scrutiny. A recombinant human lysozyme and a recombinant human albumin answer all three with no egg or blood input.